Rearrangement of Mitochondrial Pyruvate Dehydrogenase Subunit Dihydrolipoamide Dehydrogenase Protein-Protein Interactions by the MDM2 Ligand Nutlin-3. by Way, Luke et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rearrangement of Mitochondrial Pyruvate Dehydrogenase
Subunit Dihydrolipoamide Dehydrogenase Protein-Protein
Interactions by the MDM2 Ligand Nutlin-3.
Citation for published version:
Way, L, Faktor, J, Dvorakova, P, Nicholson, J, Vojtesek, B, Graham, D, Ball, K & Hupp, T 2016,
'Rearrangement of Mitochondrial Pyruvate Dehydrogenase Subunit Dihydrolipoamide Dehydrogenase
Protein-Protein Interactions by the MDM2 Ligand Nutlin-3.' Proteomics. DOI: 10.1002/pmic.201500501
Digital Object Identifier (DOI):
10.1002/pmic.201500501
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Proteomics
Publisher Rights Statement:
Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in
any medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Proteomics 2016, 16, 2327–2344 2327DOI 10.1002/pmic.201500501
RESEARCH ARTICLE
Rearrangement of mitochondrial pyruvate
dehydrogenase subunit dihydrolipoamide
dehydrogenase protein–protein interactions by
the MDM2 ligand nutlin-3
Luke Way1, Jakub Faktor2, Petra Dvorakova2, Judith Nicholson3, Borek Vojtesek2,
Duncan Graham4, Kathryn L. Ball1,2 and Ted Hupp1,2
1 Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
2 Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
3 CRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK
4 Centre for Molecular Nanometrology, WestCHEM, Department of Pure and Applied Chemistry, University of
Strathclyde, Glasgow, UK
Received: November 28, 2015
Revised: April 27, 2016
Accepted: June 3, 2016
Drugs targeting MDM2’s hydrophobic pocket activate p53. However, these agents act alloster-
ically and have agonist effects on MDM2’s protein interaction landscape. Dominant p53-
independent MDM2-drug responsive-binding proteins have not been stratified. We used as
a variable the differential expression of MDM2 protein as a function of cell density to identify
Nutlin-3 responsive MDM2-binding proteins that are perturbed independent of cell density
using SWATH-MS. Dihydrolipoamide dehydrogenase, the E3 subunit of the mitochondrial
pyruvate dehydrogenase complex, was one of two Nutlin-3 perturbed proteins identified fours
hour posttreatment at two cell densities. Immunoblotting confirmed that dihydrolipoamide
dehydrogenase was induced by Nutlin-3. Depletion of MDM2 using siRNA also elevated di-
hydrolipoamide dehydrogenase in Nutlin-3 treated cells. Mitotracker confirmed that Nutlin-3
inhibits mitochondrial activity. Enrichment of mitochondria using TOM22+ immunobeads
and TMT labeling defined key changes in themitochondrial proteome after Nutlin-3 treatment.
Proximity ligation identified rearrangements of cellular protein–protein complexes in situ. In
response to Nutlin-3, a reduction of dihydrolipoamide dehydrogenase/dihydrolipoamide acetyl-
transferase protein complexes highlighted a disruption of the pyruvate dehydrogenase complex.
This coincides with an increase in MDM2/dihydrolipoamide dehydrogenase complexes in the
nucleus that was further enhanced by the nuclear export inhibitor Leptomycin B. The data
suggest one therapeutic impact of MDM2 drugs might be on the early perturbation of specific
protein–protein interactions within the mitochondria. This methodology forms a blueprint for
biomarker discovery that can identify rearrangements of MDM2 protein–protein complexes in
drug-treated cells.
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1 Introduction
The ubiquitin conjugation system has emerged as an
extensive landscape of untapped potential for drug discovery
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Significance of the study
Reactivating the p53 tumor suppressor forms a central strat-
egy in anti-cancer therapeutics. Drugs are being developed
that target a key inhibitor of p53, named MDM2. In cell
lines and in the clinic, MDM2-targeted drugs can have par-
tial agonist effects. Identifying dominant non-p53 targets of
these MDM2-targeted drugs would improve patient stratifi-
cation. In this study, we use SWATH-based MS to identify
the most dominant target that responds at an early time
after drug treatment. We identified mitochondrial proteins
and the pyruvate dehydrogenase complex in particular as a
selective target of a MDM2-targeted drug. This methodology
forms a blueprint for biomarker discovery that can iden-
tify rearrangements of MDM2 protein–protein complexes in
drug-treated cells.
[1]. Ubiquitination can impact on protein turnover, specific-
activity, and trafficking [2]. Ubiquitin attachment requires
the concerted action of an E1, initiator ubiquitin-activating
enzyme; an E2, ubiquitin-conjugating enzyme; and an E3,
ubiquitin-ligase adaptor thatmediates ubiquitin transfer onto
a substrate [3]. The E3 ligases can be divided into HECT or
RING domain (which includes U-Box and PHD) containing
proteins. The proto-oncogene, MDM2, is a RING-domain
containing E3-ubiquitin ligase that regulates the function of
the p53 tumor suppressor [4]. The dominant role of MDM2
as an inhibitor of p53 has led to the identification of small
molecules that bind to the N-terminal hydrophobic cleft
of MDM2 leading to the activation of p53 transcriptional
activity [5].
With the compelling scientific case for reactivating the
wild-type (wt)-p53 pathway by targeting MDM2, there are
numerous MDM2 ligands in preclinical or clinical trials [1].
Human sarcomas often exhibit mdm2 gene amplification [6]
[7] and such patient groups provide a test-bed for MDM2
targeted therapeutics. Indeed, small molecules have recently
been evaluated in clinical trials in mdm2-amplified sarcomas
with partial success; more than half of patents exhibiting “sta-
ble” disease [8]. The lack of tumor regression in themajority of
patients in this trial appears to be due to “on-target toxicity” or
an “agonist property”with this class ofMDM2drug [9]. For ex-
ample, Nutlin-3 can stabilize the oncoprotein Notch [10] and
it follows that the balance of stabilization of tumor suppressor
or oncoproteins can tip the balance of tumor regression. Non-
p53 companion biomarkers are required to identify MDM2-
drug responsive or resistant patients [11]. This is consistent
with recent data suggesting that MDM2 has emerging onco-
genic roles and “druggable” functions that are independent
of p53 [12–14]. So one key question we need to ask to improve
patient response to MDM2 directed drugs is by what mecha-
nisms could the Nutlins promote an “on-target toxicity”?
The Nutlin family of molecules bind to the hydrophobic
pocket of MDM2 mimicking its inhibitory interaction with
the transactivation domain of p53 [15]. This activates p53 tran-
scription by dissociating the p53-MDM2 complex [5]. Nutlin
does not however inhibit MDM2 E3-ligase activity [16]. In
fact research has shown that Nutlin functions as an allosteric
agonist promoting a lower affinity, but physiologically sig-
nificant, interaction between the core DNA-binding domain
of p53 and the central acidic domain of MDM2 [16, 17]. It is
this second interaction between p53 and its oncogenic E3-
ligase partner that constitutes an “ubiquitination signal” for
p53 ubiquitination. More recently, the prooncogenic protein
Notch has been shown to bemonoubiquitinated and activated
by MDM2 using the same “dual-site” mechanism as MDM2
uses for p53 [10]. Nutlin can also promote the deoligomeriza-
tion of NPM [18] providing additional evidence for an agonist
effect of Nutlin on MDM2 protein–protein interactions. The
Nutlin-3 responsive proteins can be stratified with respect to
p53-like “BOX-I” homology motifs that identify a relatively
large set of p53-like MDM2-binding proteins whose equilib-
rium binding to MDM2 is disturbed by Nutlin-3 [11].
Based on the information introduced above, cell-based
quantitative proteomics screens were set up that aimed to
identify dominant subcellular organelles that are affected rel-
atively early after Nutlin-3 treatment and that could explain
its “on target toxicity” [9]. Our hypothesis is focused on the
concept that Nutlin-3 can promote changes in the MDM2-
interactome by either dissociating existing PPIs or induc-
tion of newMDM2 interactions. Our experimental design in-
cluded cells grown at two different densities and treated with
Nutlin-3, since cell density changes can alter MDM2 steady-
state levels [19] and cell density can impact on p53 activity [20].
We identified mitochondrial proteins as a group of proteins
responding early to Nutlin-3 treatment and have validated key
changes in the protein–protein interaction partners of onemi-
tochondrial protein within the pyruvate dehydrogenase com-
plex. These data highlight the pronounced effect Nutlin-3
has on the integrity of mitochondrial proteome and is con-
sistent with a previous report that identified mitochondrial
perturbation as a key effect of Nutlin-3 [21]. This proteomics
platform can facilitate defining biomarkers of Nutlin-3 that
mediate drug response or resistance using clinical samples
in the future.
2 Materials and methods
2.1 Cell culture
HCT116 cells were grown in McCoys 5A Medium including
10% fetal bovine serum at 37˚C with 5% CO2. Treatment
of cells with either 0.05% DMSO or 20 M Nutlin-3 (Enzo
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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Life Sciences) was executed 4, 8, or 24 h before an experi-
ment, as indicated in the figure legends. MitoTracker Red
CMXros (100 nM) and Leptomycin B (40 nM) were added
in proximity ligation experiments 45 min prior to fixing. For
Western blotting cells were either scraped at 40% cell den-
sity (lower confluence) or at 80% cell density (higher conflu-
ence) for experimental use. Following washing with ice cold
PBS, the cells were lysed in Urea lysis buffer (8 M Urea, 25
mM HEPES (pH7.5), 25 mM NaCl, 0.05% Triton x-100, and
5 mM DTT) for 15 min on ice, centrifuged at 13 000 rpm for
15 min and the supernatant saved. Protein concentrations
were determined by the Bradford method [22]. Samples
for MS (either SWATH or Tandem Mass Tag [TMT] label)
were scraped and lysed using UA buffer (8 M Urea, 0.1
M Tris-Cl (pH 8), and a protease inhibitor mixture; Cal-
biochem; 539134), at approximately 5 cell-pellet volumes.
Following pellet resuspension, lysates were snap frozen,
thawed, sonicated (Sonics, Vibra-CellTM, Sonics & materi-
als, Danbury, USA), and then centrifuged at 14 000 rpm for
30 min at 4˚C. The supernatant was saved and protein con-
centration was determined by BCA (according to manufac-
turer’s protocols; Thermo fisher; kit code 23225). For siRNA
treatment, A375 cells were transfected with 50 nm MDM2
SMARTpool siRNA (Dharmacon #M-003279-04-0010) using
DharmaFECT-4 reagent and incubated for 24 h. Cells were
then treated with either 0.05% DMSO or 20 M Nutlin-3
for 4 h before harvesting and lysing using urea lysis buffer.
Nontargeting siRNA (Dharmacon 001810-10-05) was used in
parallel as a control.
2.2 Protein purification
wt-dihydrolipoamide dehydrogenase and wt-MDM2 were
cloned into pDEST17 vector, containing glutathione S-
transferase N-terminal tag, expressed into BL21 (DE3) com-
petent E. coli cells and grown O/N. The dihydrolipoamide
dehydrogenase gene was obtained from Origene (RG200639
DLD (GFP-tagged)—Human dihydrolipoamide dehydroge-
nase). The cells were subcultured and induced with 1M IPTG
afterOD0.4 had been reached. After 3 h the cellswere pelleted
and incubated with lysis buffer (10% sucrose, 50 mM Tris
(pH 8), 150 mM NaCl, 3 mg Lysozyme, 0.5% NP40, 5 mM
DTT, 1 mM Benzamidine, 20 g/mL leupeptin, 1 g/mL
aprotinin, 2 g/mL pepstatin, 10 g/mL soybean trypsin in-
hibitor, 1 mM EDTA) for 45 min before a 1-min incubation
at 37˚C and sonication on ice. The lysates were then cen-
trifuged at 4000 rpm for 15 min and the supernatant added
to glutathione sepharose 4B beads and incubated for 2 h
at 4˚C. The beads were washed using wash buffer (20 mM
HEPES (pH 7.5), 1 mM DTT, 10% glycerol, 150 mM NaCl)
before elution buffer (25 mM HEPES (pH 7.5), 1 mM DTT,
10% glycerol, 150 mM NaCl) containing PreScission pro-
tease. Purification of proteins was accessed using Coomassie
staining and Western blotting. P53 was purified according to
prior methods [23]. The crude lysate derived from E. coli cells
overproducing p53 from T7.7 promoter after IPTG induction
(Fraction I) was diluted fivefold in Buffer B (25 mm HEPES
(pH8.0), 0.1 mM EDTA, 1 mM Benzamidine, 1 mM DTT)
and applied to a Hi-Trap Heparin-Sepharose column. Bound
protein was eluted with a 10 column volume linear gradient
in Buffer E from 0.1–1 M KCL. Fractions of p53 were iden-
tified by ELISA, were pooled, (Fraction II), diluted fivefold
with Buffer B, and applied to a cellulose-phosphate column.
Bound protein was eluted with a 20 column volume linear
gradient in Buffer B from 0.1–1 M KCL.
2.3 Protein–protein interaction assays
Polystyrene solid-phase microtiter wells (Costar; 07-200-336)
were coated with 100 ng of purified wt-dihydrolipoamide de-
hydrogenase or wt-p53 in 0.1 M NaHCO3 (pH 8.6). The plate
was blocked with 3% BSA/0.1% PBS-Tween-20 after which
a titration of wt-MDM2, that had been incubated with either
0.05% DMSO or 20 M Nutlin-3 for 15 min at RT, was incu-
bated in the wells for 1 h at RT. Following washing in 0.1%
PBS-Tween-20 2A10mAb (1:1000) was used to detectMDM2,
the plate washed and incubated with HRP-tagged rabbit anti-
mouse secondary antibody (1:2000). After final washes with
0.1% PBS-Tween-20, ECL solution was added and the As-
cent Fluoroskan plate reader at 450 nm used to quantify the
experiment.
2.4 Proximity ligation and Immunofluorescence
assays
HCT116 cells were grown in six-well plates over glass cover-
slips (16 mm diameter) until 50% confluency was achieved
with cells treated with 0.05% DMSO or 20 M Nutlin-3 as
described earlier. The cells were fixed onto slides with 4%
paraformaldehyde in PBS for 20 min at RT, permeabilized
for 10min in 0.25% Triton x-100 in PBS and blocked with 3%
BSA in PBS for 30 min. Antibodies from different species
were then incubated on the slides, with combinations of
MDM2 mouse mAb (4B2) with either rabbit pAb DLD (sc-
135027; Santa Cruz) or p53 (CM-1), at a 1:250 dilution for
1 h at RT. Following PBS washes IF coverslips were incu-
bated with either 594 nm goat anti-mouse or 488 nm Donkey
anti-rabbit antibodies for 1 h at RT. IF coverslips were fur-
ther washed in PBS stained with DAPI and mounted onto
slides with fluorescent mounting medium. Proximity liga-
tion assay (PLA) was carried out with the OLIGO duolink [24]
designated protocol using anti-mouse and anti-rabbit probes
(Sigma; The duolink probe product numbers are 92002 (rab-
bit plus), 92004 (mouse minus), and the duolink green detec-
tion is 92014.) The PLA coverslips were stained with DAPI
andmounted in the same fashion as the IF coverslips. Images
were taken at 40X using an Olympus BX51 microscope.
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2.5 Sample preparation for MS
Samples were trypsinized according to previously published
methods for FASP (filter-assisted sample preparation) di-
gestion protocols [25]. The filter unit (Hydrosart—stabilized
cellulose-based membrane; Vivacon 500 mL (Sartorius Ste-
dim Biotech, Germany); product number is: VN01H02
with a 10 kDa cutoff). The filter unit was washed with
100 L of a buffer containing 8 M Urea, 0.1 M Tris/HCl
pH 8.5 (UA) centrifuged at 14 000 rpm/15 min (room tem-
perature). Two hundred microliters of UA buffer and 100 g
of the protein sample in urea lysis buffer was added to the fil-
ter unit followed by centrifugation for at 14 000 rpm/15 min
(room temperature). This step results in proteins absorbing
to the matrix and removal of the lysis buffer components.
UA buffer containing 16.7 mM TCEP was then added fol-
lowed by incubation in a thermomixer for 600 rpm/30min
(37˚C) followed by centrifugation for 14 000 rpm/15 min
(room temperature). This step results in reduction of any
disulfide bonds in the denatured proteins. The filter unit was
then incubated with UA containing 50 mM iodoacetamide in
the dark for 20 min at room temperature before further cen-
trifugation at 14 000 rpm/15 min. This step catalyzes alkyla-
tion of free sulfhydryl groups to form S-carboxyamidomethyl-
cysteine that cannot be reoxidized thus permitting maximal
tryptic cleavage. The filter unit was washed with a buffer
containing 100 mM NH4HCO3, centrifuged at 14 000 rpm/
15 min (room temperature). A buffer containing 50 mM
NH4HCO3 (100 L) and trypsin in a mass ratio 1:30
(trypsin/protein) was added to the filter, the samples were
mixed at 600 rpm/1min, and then incubated for 18 h in a wet
chamber (37˚C). Two rounds of subsequent centrifugation
14 000 rpm/15 min (room temperature) eluted the peptides.
The peptide purification of samples followed with the evapo-
rated samples being resuspended in 0.1% formic acid (FA).
Micro SpinColumns C-18 (25–75 L) (Harvard Apparatus,
USA) were conditioned twice with 100% ACN/0.1% FA, be-
fore washing with 0.1% FA. The column was hydrated for
15 min in 0.1% FA, centrifuged and the sample peptides
added. After centrifugation (500 rpm/2 min), peptides were
eluted from the column using three buffers, first with
50% ACN and 0.1% FA in water, second in 80% can and
0.1% FA in water and third composed from 0.1% FA in
ACN. Subsequently, the samples were evaporated using a
SpeedVac.
2.6 SWATH-MS
SWATH method for label-free quantification of proteins
in complex mixtures was set-up according to previously
published methods [26]. TripleTOF 5600+ (AB-SCIEX,
Toronto, Canada) operated in high sensitivity positive mode.
Random precursor ion peaks were extracted from TOF-MS
and the approximate chromatographic peak width was de-
fined to correctly establish SWATH method so that at least
ten data points were acquired across a peak. Four randomly
extracted precursor peaks from TOF-MS were evaluated and
the peak width at FWHM was in average 1.5 min, so the cy-
cle time of SWATH was set to 3.5 s. With the defined cycle
time an optimal SWATH width of 20 Da with 1 Da overlap
was calculated, with accumulation time 98 ms per SWATH.
Precursor range was selected from 400 amu up to 1100 amu.
Product ion rangewas scanned from300 amuup to 1600 amu
and rolling collision energy was used with collision energy
spread (CES) of 10 mV. Spectral library for SWATH data
mining was measured from 1 L pool of cell lysates (ap-
prox. 1 g/L protein concentration). Mass spectrometer
TripleTOF 5600+ (AB-SCIEX, Toronto, Canada) operated in
data-dependent mode. During each cycle, mass spectrometer
fragmented the top 20 intense precursor ions with exclusion
time set to 12 s. Minimum precursor ion intensity was set to
50 cps, 100ms accumulation time was used and 150ms accu-
mulation time for TOF-MS scan. For building up of spectral
library 1632 proteins FDR 1% were used after Protein Pi-
lot 4.5 (AB-SCIEX, Toronto, Canada) search using Uniprot
2013_12 database. Spectral library was built in Peakview soft-
ware 1.2.0.3 (AB-SCIEX, Toronto, Canada), only the identi-
fications below FDR of 1% were indexed. Quantitative data
(peak areas) corresponding to each protein included in spec-
tral library were extracted from SWATH data using manual
analysis in Peak view 1.2.0.3 (AB-SCIEX, Toronto, Canada).
Data were extracted using retention time window of 3.5 min,
which was determined by extracting random peaks across LC
gradient (Fig. 2A and B). Retention time window describes
the LC retention time shifts between SWATH technical repli-
cates and data dependent acquisition (DDA) measurement
and specifies in which scope of retention times software
should look for peaks included in spectral library (DDAmea-
surement result). Eight peptides per protein and five prod-
uct ions per each peptide were used. Extracted quantitative
data were further analyzed in Marker view where T-testing
was done on quantitative data from all replicates originating
from compared sample pair. As a result, for all proteins in
spectral library protein fold changes and p values (in Sup-
porting Information Tables 1 and 2) between chosen sample
pair were calculated and are valid only for the concrete pair
comparison.
2.7 Isobaric (TMT) labeling of TOM22+
antibody-enriched mitochondrial proteins
Mitochondrial isolation and lysis was performed according
to the protocols defined by the Miltenyl Biotec mitochondrial
isolation kit (product code 130-094-532). Cells processed in
biological duplicates were lysed in urea buffer (100 L of 8 M
urea in 0.1 M Tris-Cl, pH 8) containing protease inhibitors
(1:100; as above). Samples weremixed by pipetting and stored
overnight in the fridge, then were sonicated and centrifuged
at 14 000 rpm at 4C for 30 min. The proteins concentra-
tion was determined by the RCDC kit (Bio Rad; 5000121).
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Proteins were digested into peptides with the FASP protocol
[25] and detailed as above. Fifty micrograms of peptides per
sample were labeled with TMT labels, according to Thermo
Fisher Scientific (TMT 10plexTM Label Reagent Set, Prod #
90111, Lot# QB213026). The tags, the mass, and the sam-
ple connections are summarized in Fig. 5A. Peptides were
separated using Thermo Scientific UltiMate 3000 RSLCnano
chromatograph. Sample was loaded on a precolumn (Thermo
Scientific-precolumn, 30m id, 5mm length, C18 PepMap
100, 5 m particle size, 100 A˚ pore size) and peptides further
separated on a Thermo ScientificTM Acclaim PepMap RSLC
column (75 m id, length 500 mm, C18, particle size 2 m,
pore size 100 A˚) using a 300 nL/min flow rate with a linear
gradient of B (80% ACN in 0.08% aq. formic acid) in A (0.1%
aq. formic acid). The gradient composition used for peptides
separation was as follows highlighting time as a function of
%B: 0 min, 2%B; 10 min, 2%B, 200 min, 50%B, 210 min,
98%B, 228 min, 98%B, 255 min END. Peptides eluting from
the column were introduced into Thermo ScientificTM Orbi-
trap EliteTM operating in Top10 data-dependent acquisition
mode. The data acquisition parameters setting for the Top10
method include: MS1 includes a mass range of 335–1800,
a resolving power setting of 120 000, and a Max. in time of
200 ms; MS2 includes: HCD activation type; a min. signal
required of 5000, an isolation width of 1.2, NCE of 35, charge
rejection state is unassigned; 1+; dynamic exclusion settings
are ON; the exclusion width is 10 ppm; repeat count is set at
1; the exclusion list size is 500; and the exclusion duration is
30 s.
2.8 Database searching and analysis
The data were processed with a Proteome Discoverer1.4
(Thermo ScientificTM), employing Mascot with the follow-
ing search settings: database Swiss-Prot human (April 2015);
enzyme trypsin; two missed cleavage sites; precursor mass
tolerance 10 ppm; fragment mass tolerance 0.6 Da; dy-
namic modifications: formyl [peptide N-terminus], oxidation
[M], Gln to pyro-Glu [peptide N-terminus], acetyl [protein
N-terminus], TMT6plex [K], TMT6plex [N-term], and static
modification: carbamidomethyl [C]. The results of the search
were further submitted to generate the final report using a
cutoff of 1% FDR on peptide levels and only unique pep-
tides were used for protein quantitation. The quantitative
option was enabled with the corresponding combination of
labeled peptides in the sample type and the observed rel-
ative quantification ratio was normalized compared to the
median. Proteins with a fold change of 2.0 were considered
as highly differentially expressed (Fig. 5C) and using a less
stringent cut-off of 1.5-fold changes we identified a larger
list of mitochondrial proteins (Table 1). MS/MSALL SWATH
data and MS/MS data from TMT experiment are uploaded in
PRIDE.
3 Results
3.1 Designing an experimental plan to identify novel
MDM2 drug-responsive-binding proteins
There are over one-hundred published MDM2-binding pro-
teins that have been discovered using a large range of cell
types, methodologies, and experimental conditions [27]. This
vast number of MDM2-interactors has not been integrated
intoMDM2“signaling pathways.” These target proteins could
act as biomarkers to predict MDM2 drug responses but
identifying such “core” MDM2-binding proteins using tissue
culture approaches is complicated by the fact that cell density
can have a significant effect on p53 protein synthesis [28] and
on the steady-state levels of MDM2 protein through phos-
phorylation of its pseudo-substrate motif [19,28]. In addition,
cell density changes created by changing the cell number at
time of seeding also can attenuate p53-dependent biological
processes; this effect of cell density is not a consequence of
density-dependent cell-cycle changes but rather are linked to
cadherin-mediated cell-cell junctions [20]. Thus, it is likely
that density effects on MDM2 levels will alter its steady-state-
binding proteins that in turn impacts on the balance between
oncoprotein or tumor suppressor protein stabilization. Such
a density effect might explain in part the striking heterogene-
ity of p53 protein stabilization in primary human tumors in
cancer tissue [29]. Our experimental design in this current
study aimed to use the same wt-p53 containing cancer cell
line plated at two different cell numbers that show differen-
tial MDM2 induction, but similar p53 induction, by Nutlin-3
(Fig. 1). The use of the same cell line plated at two differ-
ent densities would allow us to subtract any density-specific
contributions to MDM2 drug responses. This would produce
a very stringent screen to identify only those proteins that
commonly change upon Nutlin-3 treatment independent of
MDM2 protein differential stabilization (Fig. 1A).
3.2 Identification of the most significantly perturbed
proteins induced by the MDM2 ligand Nutlin-3
at two cell densities that reflect differential
MDM2 protein induction
Wedefined the parameters thatmeasured differentialMDM2
protein levels as a function of differences in the cell number
at the time of cell plating. The treatment of HCT116 cells
(p53+) with Nutlin-3 at 40 or 80% plating density resulted in
higher MDM2 protein induction at lower compared to higher
cell plating density (Fig. 1B–D, lanes 7 versus 8). This is
consistentwith previous data showing that either endogenous
or transfected MDM2 protein has lower steady-state levels at
higher cell density [19, 28].
We aimed to identify proteins whose levels were af-
fected most significantly by Nutlin-3 independent of cell
plating density (e.g. MDM2 protein levels) and then to link
these targets to changes in key cellular phenotypes. HCT116
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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Table 1. Data summarize the proteins showing the highest fold change (elevated or reduced peptide IDs) after Nutlin-3 treatment in the
mitochondrial immunoprecipitation using TMT
Accession Gene name Protein name Mitochondrial? Fold change
Nutlin/DMSO [1] Nutlin/DMSO [2]
A. Nutlin-3 upregulated proteins in TOM22+ mitochondria
O60814 H2B1J Histone H2B type 1-J No 3.75 2.19
P06899 H2B1K Histone H2B type 1-K No 3.69 1.88
P14927 NDUA2 NADH dehydrogenase 1 alpha subcomplex subunit 2 Yes 2.03 2.40
P51970 QCR7 Cytochrome b-c1 complex subunit 7 Yes 1.91 1.96
P52815 NH2L1 NHP2-like protein 1 No 1.78 1.84
P55769 RUVB2 RuvB-like 2 No 1.66 1.63
Q9Y230 RM12 39S ribosomal protein L12 Yes 1.56 1.90
O43678 NDUA8 NADH dehydrogenase 1 alpha subcomplex subunit 8 Yes 1.52 1.98
B. Nutlin-3 downregulated proteins in TOM22+ mitochondria
P62805 HIST1H4A Histone H4 No 0.09 0.12
Q8NDV3 SMC1B Structural maintenance of chromosomes protein 1B No 0.14 0.46
Q9UJF2 RASAL2 Ras GTPase-activating protein nGAP No 0.18 0.40
Q6SA08 TSSK4 Testis-specific serine/threonine-protein kinase 4 No 0.20 0.47
Q9BPU6 DPYSL5 Dihydropyrimidinase-related protein 5 No 0.21 0.36
P01008 SERPINC1 Antithrombin-III No 0.22 0.31
Q8IUG5 MYO18B Unconventional myosin-XVIIIb No 0.24 0.50
P02768 ALB Serum albumin No 0.24 0.42
P05141 SLC25A5 ADP/ATP translocase 2 Yes 0.28 0.44
Q03181 PPARD Peroxisome proliferator-activated receptor delta No 0.28 0.64
P12236 SLC25A6 ADP/ATP translocase 3 Yes 0.32 0.39
Q00325 SLC25A3 Phosphate carrier protein Yes 0.32 0.49
O95202 LETM1 LETM1 and EF-hand domain-containing protein 1 Yes 0.34 0.26
P13645 KRT10 Keratin type I cytoskeletal 10 No 0.34 0.28
P35908 KRT2 Keratin type II cytoskeletal 2 epidermal No 0.35 0.37
Q6NXT2 H3F3C Histone H3.3C No 0.36 0.27
P35527 KRT9 Keratin type I cytoskeletal 9 No 0.37 0.21
P10412 HIST1H1E Histone H1.4 No 0.39 0.37
P04264 KRT1 Keratin type II cytoskeletal 1 No 0.40 0.25
Q04837 SSBP1 Single-stranded DNA-binding protein Yes 0.41 0.67
P07900 HSP90AA1 Heat shock protein HSP 90-alpha No 0.43 0.62
P00403 MT-CO2 Cytochrome c oxidase subunit 2 Yes 0.43 0.61
P27824 CANX Calnexin Yes 0.43 0.36
P19338 NCL Nucleolin No 0.47 0.60
O00217 NDUFS8 NADH dehydrogenase iron-sulfur protein 8 Yes 0.52 0.65
P68104 EEF1A1 Elongation factor 1-alpha 1 No 0.54 0.63
P08238 HSP90AB1 Heat shock protein HSP 90-beta No 0.57 0.52
P02656 APOC3 Apolipoprotein C-III No 0.58 0.30
O43707 ACTN4 Alpha-actinin-4 No 0.59 0.58
Q8NEY8 PPHLN1 Periphilin-1 No 0.60 0.49
P56537 EIF6 Eukaryotic translation initiation factor 6 No 0.61 0.65
Q8IY81 FTSJ3 pre-rRNA processing protein FTSJ3 No 0.66 0.42
The raw data (Supporting Information Tables 3 and 4) were normalized over the internal average for each replicate. The p value using a
paired t-test is 0.269194 indicating that the two datasets are not significantly different. The samples are highlighted with respect to whether
or not they are classically known to bemitochondrial proteins (shaded) with the caveat that some proteins, like histones, have been recently
reported to interact with mitochondria [45–47].
(p53+ and isogenic p53-null) cells were grown in parallel to
40 or 80% density and treated with DMSO control or Nutlin-3
for 4 h. The use of the same cell line at two different densities
where MDM2 protein levels are differential stabilized pro-
vides a subtraction of density-specific contributions toMDM2
protein stabilization. Cells from two densities were then har-
vested and subjected to differential protein quantitation us-
ing label-free methodologies (SWATH-MS [26]; Supporting
Information Fig. 1A and B; Supporting Information Tables 1
and 2). It is important to point out that SWATH analysis
involved the application of three technical replicates of each
sample, but that there are no biological replicates of each
sample. This precludes us developing statistically signifi-
cant pathway maps at two cell densities, but it allows us to
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Figure 1. The allosteric effect of Nutlin-3 on MDM2 functions. (A) MDM2 has multiple functional domains including an N-terminal peptide-
binding groove that is the binding site of Nutlin-3 [5]; a central domain that responds allosterically to N-terminal MDM2-binding ligands
(like Nutlin-3) to increase p53 binding and ubiquitination (arrows) [16], and a RING domain that is required for E2 docking [49] and allosteric
control of ubiquitination by the E2, UBCH5 [19]. N-terminal domain Nutlin-3 binding by MDM2 can stimulate p53 ubiquitination [16],
stimulate ubiquitin-dependent protein activation of Notch [10], and direct binding to alter target protein oligomerization of NPM [50]. Thus,
Nutlin-3 can dissociate or induce various protein–protein interactions due to the allosteric effects of ligands on MDM2 function. These data
suggest a complex effect of MDM2 ligands on changes in the steady-state cellular proteome. (B–D) HCT116 cells (p53+ and p53-null, as
indicated) where grown to 40 and 80% density as defined in the methods. Cells were treated with Nutlin-3 (20 M final concentration) or
DMSO control and after 4 h cells were harvested for lysis without proteasome inhibitor treatment (that would artificially elevate levels of
target protein). Lysates were blotted with the indicated antibodies (MDM2, p53, and tubulin as a loading control). The data demonstrate
that p53 protein is induced equivalently by Nutlin-3 at either cell density, but MDM2 protein exhibits higher steady-state levels at the lower
density after Nutlin-3 treatment, as reported previously [19].
identify outlier responders that require orthogonal validation
for confirmation. The four-hour time point was used since
this precedes major visible changes in cell phenotype and is
the time point previously shown to begin to reveal changes
in dozens of proteins [18]. Both samples were processed in
triplicate; for example, the total ion current (TIC) from three
technical replicates of Nutlin-3 p53+ sample from 40% den-
sity is shown in Supporting Information Fig. 1A and B. This
defines the accuracy of the autosampler sample pickup and
reproducibility of sample loading. The numbers of proteins
identified at 40% cell density were 1540 and those at 80% cell
density were 1535 (Supporting Information Tables 1 and 2).
Proteins that changed 2-fold or greater as defined by SWATH-
MS in response to Nutlin-3 (increased or decreased peptide
ion quantitation) at both low and high cell densities were tab-
ulated (Fig. 2A). These data are depicted in a scatter plot of
total protein changes (as defined by increased or decreased
peptide ion quantitation) as a function of both densities (e.g.
biological replicates) (Fig. 2B). Only two proteins changed by
more than 2 x log2 at both densities (Fig. 2B); those being the
mitochondrial protein dihydrolipoamide dehydrogenase [30]
and the nucleosome interacting protein LRWD1 [31]. Addi-
tional mitochondrial protein changes (increased or decreased
peptide ion quantitation)were also identified byNutlin-3 such
as NADH dehydrogenase subunit 5, the chaperone GRPEL1,
mitochondrial 28S ribosomal protein MRPS35, mitochon-
drial acyl-coenzyme A thioesterase 9, citrate synthase, and
mitochondrial enoyl-coA hydratase (Fig. 2A and B; Support-
ing Information Tables 1 and 2). As samples were not pro-
cessed as biological replicates, this precludes the formation of
statistically significant “pathway maps.” As such, we focused
on validation of individual outliers as potential core MDM2
interactors.
Dihydrolipoamide dehydrogenase was evaluated immuno-
chemically and at either cell density two effectswere observed;
the full-length isoform of dihydrolipoamide dehydrogenase
was induced by Nutin-3 and the lower isoform of di-
hydrolipoamide dehydrogenase was reduced by Nutlin-3
(Fig. 3A). It is important to note that, although fold
changes in peptide ions identified from dihydrolipoamide
dehydrogenase (and other proteins; Supporting Information
Tables 1 and 2) can be used to define protein changes as
being “up or downregulated” at the different densities, this
does not necessarily reflect changes in absolute steady-state
protein levels. It might reflect the extractability, PTM, and
trypsinization capacity that give rise to peptide ion identifi-
cation and then quantitation using MS. For example, tryptic
dihydrolipoamide dehydrogenase peptide ions are elevated
by Nutlin-3 at 40% cell density, but are suppressed at 80%
cell density (Fig. 2A and B). However, total dihydrolipoamide
dehydrogenase protein upper isoform is elevated by Nutlin-3
at both cell densities and the lower isoform is suppressed at
both cell densities as defined by immunoblotting. Different
buffers are used for immunoblotting and sample process-
ing for SWATH-MS. Nevertheless, these data highlight that
the mitochondrial protein dihydrolipoamide dehydrogenase
protein is perturbed by Nutlin-3. Given the prior report that
Nutlin-3 promotes the generation of mitochondrial reactive
oxygen species and p53 protein translocation [21, 32], we fo-
cused in this study on evaluating mitochondrial proteome
changes when MDM2 is perturbed at early time points af-
ter Nutlin-3 treatment and whether this is linked to novel
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Figure 2. Identification of pro-
teins with the most differen-
tial change at 40 and 80% cell
density in response to Nutlin-
3 treatment. (A) Identification of
proteins perturbed by Nutlin-3
using SWATH MS. HCT116 cells
were incubated for 4 hwithNutlin-3
under conditions in which MDM2 is
just beginning to be stabilized (Fig.
1B). This ensures that we capture
changes in the cellular proteome
just when MDM2 is starting to be
perturbed in cells by Nutlin-3. The
cell pellets were processed using
MSSWATH [26] to identify differen-
tially perturbed proteins (Support-
ing Information Tables 1 and 2),
some of which are highlighted (in
green) as a function of 40 or 80%
cell density. (B) A scatter plot of
the total protein changes as a func-
tion of cell density and fold change
(log2) with mitochondrial proteins
highlighted in red.
MDM2-mitochondrial-binding proteins. We also employed
siRNA as an approach to target MDM2 and examine effects
on dihydrolipoamide dehydrogenase protein levels. siRNA
is complicated to use since it also activates the interferon
response [33]. In addition, siRNA depletion of MDM2 is
known to activate p53 (Fig. 3B), which in turn inducesMDM2
protein so that MDM2 levels are only attenuated by siRNA
(Fig. 3B). Nevertheless, this treatment can induce the upper
isoform of dihydrolipoamide dehydrogenase (Fig. 3B). These
data support the idea that “inhibiting”MDM2with the ligand
Nutlin-3 or with siRNA (that both stabilize p53 protein) can
induce dihydrolipoamide dehydrogenase.
3.3 Evaluation of global effects of Nutlin-3 on
the mitochondrial proteome and respiration
As dihydrolipoamide dehydrogenase is a mitochondrial pro-
tein, we evaluated whether Nutlin-3 might change mitochon-
dria activity. If so, this would suggest that one dominating
effect of Nutlin-3 on cell integrity resides in perturbation
of certain mitochondrial proteins. Thus, we evaluated more
global effects of mitochondrial integrity using Mitotracker,
a dye that binds to proteins in intact mitochondria with a
functional negative membrane potential and that results in
red color reflecting active mitochondria [34]. At four or eight
hour time points there was little change in the bioactivity of
mitochondria using this assay (Fig. 4A–C versus 4D–F; 8-h
time point). By 24 h where nuclear morphology remains in-
tact, significant loss ofmitochondrialmembrane potential (as
defined by loss of red color) was observed in Nutlin-3 treated
cells (Fig. 4G-I versus and 3J-L).
Next, we evaluated whether we could observe changes in
the mitochondrial proteome four hours post-Nutlin-3 treat-
ment by purifying mitochondria using antibody coupled su-
perparamagnetic beads that bind to the TOM22 outer mem-
brane receptor of mitochondria (Fig. 5A [35]). Using this
method, we performedmitochondrial immunoprecipitations
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Figure 3. Immunochemical analysis of dihydrolipoamide dehydrogenase protein levels after MDM2 perturbation. (A and B) HCT116 cells
(p53+) where grown to 40 or 80% density. Cells were treated with Nutlin-3 (20 M final concentration) or DMSO control and after 4 h,
cells were harvested for lysis without proteasome inhibitor treatment that would artificially elevate levels of target protein. Lysates were
blotted with the indicated antibodies to dihydrolipoamide dehydrogenase and tubulin as a loading control. (C–F). HCT116 cells grown at
80% density and then were treated with control siRNA (C) or siRNA to deplete MDM2 (M) for 24 h, followed by treatment with DMSO or
Nutlin-3. The lysates were then immunoblotted for p53, MDM2, and dihydrolipoamide dehydrogenase, and the loading control.
in two biological replicates (at 40% cell density) to define the
extent overlap of differentially responding proteins. Although
this method has an advantage of speed over traditional mul-
tiple centrifugation methods of purifying mitochondrial, its
limitation is that TOM22-mitochondria are not purified.Mito-
chondrial samples (e.g. TOM22+ fractions) from cells treated
for four hours with Nutlin-3 were first lysed and processed
using the FASP method for labeling peptides using tandem
mass tag isotopic labels[36] (Fig. 5A). A comparison of the
protein identifications using the TOM22 affinity purification
methodology between a prior study and this study is shown
in Fig. 5B.
One thing to note is the high identity of the total pro-
tein IDs in two biological replicates (Fig. 5C and Supporting
Information Tables 3 and 4). These data together suggest first
that the method can reproducibly capture “stably” associated
mitochondrial proteins in the immunoprecipitate and sub-
sequent washing steps. Second, the data suggest that there
are no major rearrangements of the abundant mitochondrial
proteome four hours after Nutlin-3 treatment. Nevertheless,
we cannot rule out that many of these proteins are contam-
inants isolated through their affinity for the magnetic bead
matrix, the TOM22 antibody coupled to the beads that en-
riches for mitochondria, or that bind mitochondrial mem-
brane proteins specifically but artifactually after tissue lysis
that disrupts subcellular organization. However, we can state
that this method is an established tool that can highly enrich
for TOM22+mitochondria [35] and that a proteomic analysis
Figure 4. The effects of Nutlin-
3 on mitochondrial membrane
permeability. HCT116 cells were
treated with Nutlin-3 for 8 or
24 h (as indicated and cells
were processed using antibod-
ies to dihydrolipoamide dehy-
drogenase (A, D, G, J), DAPI nu-
clear stain (B, E, H, K), and as a
merged image (C, F, I, L). The red
fluorescence highlights active
mitochondria, green depicts the
expression of dihydrolipoamide
dehydrogenase, and degrees
of colocalization as shades or
orange/yellow.
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Figure 5. The effects of Nutlin-3
on the proteome of TOM22+
immunoaffinity purified mito-
chondria. (A). The mass tags
used for each sample is as
indicated, without and without
Nutlin-3, done in duplicate
for a total of four samples
using a TMT labeling kit. (B)
A comparison of the protein
overlap in the TOM22 immuno-
precipitate from this study
(green) and a previous study
(red) [37]. (C) The percentage of
proteins defined to be mitochon-
drial using Mitominer (http://
mitominer.mrc-mbu.cam.ac.uk)
in the SWATH-MS datasets
versus the TMT datasets. (D)
The total protein identification
(Supporting Information Tables 3
and 4) from two independent cell
plates grown were compared to
determine the reproducibility in
protein capture. (E) Normalized
Nutlin-3 responsive changes
(twofold changes) in the mito-
chondrial proteome (TOM22+)
derived from the biological repli-
cates summarized in Supporting
Information Tables 3 and 4.
of proteins isolated by this method [37] identifies many of the
same proteins from our cell line (Fig. 3B).
Although the method reveals a high degree of overlap
in the total protein composition using TMT (Fig. 5C), both
immunoprecipitates exhibited quantitative difference in the
total average fold change in response to Nutlin-3 (Fig. 5D).
For example, sample 1 showing an average difference of
13.25 and sample 2 showing an average difference of 2.04
(Supporting Information Tables 3 and 4). This identifies
the variability in the methodology and suggests that the
washing stepsmight result in differential loss of proteins that
affects peptide yield in the isotopic label. Nevertheless, upon
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Figure 6. Nutlin-3 dissociates dihydrolipoamide dehydrogenase and dihydrolipoamide acetyltransferase protein–protein interactions
within the pyruvate dehydrogenase holoenzyme complex. (A–F) HCT116 cells were treated with DMSO or Nutlin-3 (20 M) for 4 h. Cells
were fixed and processed for proximity ligation [24] as recorded in the Methods using antibodies to dihydrolipoamide dehydrogenase
(mouse) and dihydrolipoamide acetyltransferase (rabbit). Cells were imaged using FITC as a readout of proximity ligation (representative
images in A, B, and C), DAPI plus merged FITC (D, E, and F). (A, D) DMSO control; (B, E) Nutlin-3 effects; (C, F) DMSO with BSA controls
without primary antibodies (G and H). MDM2:p53 complexes were evaluated with DMSO control (G) or with Nutlin-3 (H; representa-
tive images are a merge of FITC proximity ligation and DAPI to localize the nucleus). The quantitation of the average dihydrolipoamide
dehydrogenase/dihydrolipoamide acetyltransferase foci in cells is summarized in I (using ImageJ software).
comparison of the two replicates, and upon normalization
of the data in Supporting Information Tables 3 and 4, repro-
ducible Nutlin-3 induced changes in proteins were observed
in 40 of the 200 proteins identified in the mitochondrial
immunoprecipitation (Fig. 5D). These data are consistent
with the shotgun MS data acquired using SWATH-MS that
highlighted a relatively small change in proteome changes in
response toNutlin-3 four hours posttreatment (Fig. 2).Within
the biological replicates, we stratified those proteins com-
monly upregulated or downregulated by 1.5-fold differences
following Nutlin-3 treatment (Table 1). An apparent enrich-
ment of mitochondrial proteins using the TOM22 affinity
purification methodology was observed, relative to samples
processed using whole cell lysis by SWATH-MS (Fig. 5E).
The data identify threemitochondrial proteins with>twofold
change in expression; NADH dehydrogenase subunits are
commonly upregulated in the TOM22+ mitochondrial
fractions and both ADP/ATP translocase subunits are
commonly downregulated in the TOM22+ mitochondrial
fractions (Table 1). Additional mitochondrial proteins
that show differential protein expression (from the total
protein data in Supporting Information Tables 3 and 4) are
highlighted (Table 1). Together the data suggest that Nutlin-3
can impact on dynamics of the mitochondrial proteome
and is consistent with the concept that Nutlin-3 can alter
mitochondrial bioactivity (Fig. 4).
3.4 Changes in dihydrolipoamide dehydrogenase
protein–protein interaction landscape after
Nutlin-3 treatment
Showing that the mitochondrial proteome, mitochondrial
activity, and dihydrolipoamide dehydrogenase change after
C© 2016 The Authors. Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
2338 L. Way et al. Proteomics 2016, 16, 2327–2344
Figure 7. The effects of Nutlin-3 on
dihydrolipoamide dehydrogenase and
MDM2 complexes protein in vitro and
in vivo. (A and B) The effects of Nutlin-3
on MDM2 protein–protein interactions.
An ELISA was used to measure
the binding of MDM2 to A, dihy-
drolipoamide dehydrogenase or B, p53
[51]. The purity of the indicated pro-
teins measure by Coomassie blue is in
Supporting Information Fig. 2. Target
protein p53 or dihydrolipoamide dehy-
drogenase was coated onto the solid
phase as indicated in the Methods.
Ligand-free MDM2 (DMSO control) or
Nutlin-3 (20 M in DMSO) bound
MDM2 was titrated into reactions fol-
lowed by immunochemical quantita-
tion of the amounts of MDM2 bound.
MDM2 activity is depicted in relative
light units as a function of increasing
MDM2 protein levels (in nanograms).
(C–H) In vivo binding of MDM2 and di-
hydrolipoamide dehydrogenase. Prox-
imity ligation assays were used accord-
ing to the Methods to measure MDM2
and dihydrolipoamide dehydrogenase
binding in situ. (C and D) FITC and DAPI
merged images, respectively, in prolif-
erating cells treated with DMSO con-
trol. (E and F) FITC and DAPI merged
images, respectively, in cells treated
with Nutlin-3 (20 M) for 4 h. (G and H)
FITC and DAPI merged images, respec-
tively, in proliferating cells treated with
DMSO control using BSA in place of
primary antibodies as a negative con-
trol. (I and J) Total cellular distribution
of MDM2 and dihydrolipoamide dehy-
drogenase. Immunofluorescence was
used with specific antibodies in fixed
cells according to the Methods to mea-
sure the total distribution of MDM2
and dihydrolipoamide dehydrogenase
pools in the absence or presence of
Nutlin-3 (20 M). (K) Quantitation of
MDM2 and dihydrolipoamide dehydro-
genase protein–protein interaction foci
in the absence and presence of Nutlin-3
using proximity ligation [24].
Nutlin-3 treatment, we next determined whether (i) MDM2
forms direct interactions with dihydrolipoamide dehydroge-
nase in cells, and (ii) whether dihydrolipoamide dehydro-
genase protein interactions change in response to Nutlin-3.
Dihydrolipoamide dehydrogenase is the E3 Component of
the three proteins that comprise the pyruvate dehydroge-
nase complex [38]. We first examined as a positive control
whether dihydrolipoamide dehydrogenase (the E3 subunit)
and dihydrolipoamide acetyltransferase (the E2 subunit) form
detectable protein–protein interactions in cells and whether
in turn this was altered by Nutlin-3. Proximity ligation as-
says were used as a tool that can identify a protein–protein
interaction with a distance of 10–30 nm that is in the upper
range of that observedusingFRET (5–20nm) [24,39]. This can
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Figure 8. The effects of Leptomycin B
on dihydrolipoamide dehydrogenase
and MDM2 complexes in cells using
proximity ligation assays. (A and B)
The effects of Leptomycin B after
four hours of treatment on MDM2
and dihydrolipoamide dehydrogenase
protein–protein interactions with im-
ages depicting FITC proximity ligation
[24] (A) and DAPI nuclear stain (in
blue) and MitoTracker Red CMXros (in
red) as a merged image (B). (C and
D) The effects of Nutlin-3 on MDM2
and dihydrolipoamide dehydrogenase
protein–protein interactions with
images depicting FITC proximity
ligation (C) and DAPI nuclear stain (in
blue) and MitoTracker Red CMXros
(in red) as a merged image (D). (E
and F) The effects of Leptomycin B
and Nutlin-3 combined on MDM2
and dihydrolipoamide dehydrogenase
protein–protein interactions with im-
ages depicting FITC proximity ligation
(E) and DAPI nuclear stain (in blue) and
MitoTracker Red CMXros (in red) as a
merged image (F). (G) Quantitation of
protein–protein interaction foci with
the indicated treatment with DMSO,
Leptomycin B, Nutlin-3, or Nutlin-3,
and Leptomycin B combined.
detect authentic endogenous proteins in situ and does not rely
on transfected or artificially GFP-tagged protein vectors. Di-
hydrolipoamide dehydrogenase and dihydrolipoamide acetyl-
transferase do indeed form protein–protein interaction foci
in growing cells (Fig. 6A and D). This is consistent with
the known interaction between the two proteins as compo-
nents of the pyruvate dehydrogenase complex. The treatment
with Nutlin-3 reduced the number of dihydrolipoamide dehy-
drogenase and dihydrolipoamide acetyltransferase protein–
protein interaction foci (Fig. 6B and E and quantified in 6I).
A negative control without primary antibodies is shown
in Fig. 6C and F. As a positive control, preformed com-
plexes of MDM2:p53 in proliferating cells (Fig. 6G) are
dissociated by Nutlin-3 (Fig. 6H). Quantitation revealed that
the average number of p53:MDM2 foci per cell in control
groups was 26 and after Nutlin-3 treatment this was reduced
to an average of 12 complexes per cell (data not shown).
The data together suggest that the pyruvate dehydrogenase
holoenzyme complex is being dissociated byNutlin-3 and that
the integrity of the mitochondrial organelle is starting to be
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compromised at this relatively early time point post-Nutlin-3
treatment. This is consistent with a prior report of Nutlin-
3 inducing reactive oxygen species in the mitochondria and
causing p53 translocation to the mitochondria [21, 32].
The relatively rapid change in dihydrolipoamide dehydro-
genase after Nutlin-3 treatment might lead to a change in a
direct protein–protein complexes with MDM2. On the con-
trary, there might be no direct protein–protein interaction
between dihydrolipoamide dehydrogenase and MDM2. This
would indicate the effects of Nutlin-3 on dihydrolipoamide
dehydrogenase are indirect from MDM2. We next evaluated
whether dihydrolipoamide dehydrogenase and MDM2 form
detectable protein–protein interactions in cells and whether
in turn this equilibrium is perturbed by Nutlin-3. First, re-
combinant dihydrolipoamide dehydrogenase purified from
bacteria was able to bind to recombinant bacterially expressed
MDM2, with a marginal effect of Nutlin-3 on the protein–
protein interaction (Fig. 7A). By contrast, full-length p53 can
be dissociated more significantly by Nutlin-3 (Fig. 7B), pre-
sumably because p53 binds to MDM2 though the N-terminal
peptide-binding domain of MDM2. These data indicate that
MDM2 can form a direct complex with dihydrolipoamide de-
hydrogenase but the complex is not intrinsically sensitive to
Nutlin-3.
We next determined whether endogenous MDM2 and di-
hydrolipoamide dehydrogenase form a protein–protein com-
plex in cells. This was measured using the proximity lig-
ation assay. Using this method, we observe approximately
20–30 MDM2:dihydrolipoamide dehydrogenase foci per cell
(Fig. 7C and D) indicating that MDM2 and dihydrolipoamide
dehydrogenase can indeed form protein–protein complexes
in vivo. The number of foci is similar to that observed between
MDM2 and p53 (Fig. 6) suggesting that dihydrolipoamide de-
hydrogenase represents a relatively dominant-binding part-
ner of MDM2. In response to Nutlin-3 there is a marginal
increase in the number of dihydrolipoamide dehydrogenase-
MDM2 foci in cells (Fig. 7E and F; quantified in K).
However, this quantitation underestimates the qualitative
change in protein-interaction foci, as aggregates of dihy-
drolipoamide dehydrogenase and MDM2 form in the nu-
cleus (Fig. 7F, arrows). Approximately 20–25% of Nutlin-3
treated cells contain the aggregated nuclear dihydrolipoamide
dehydrogenase-MDM2 foci (data not shown). The total
MDM2 and dihydrolipoamide dehydrogenase pools in the
nucleus using immunofluorescence before and after Nutlin3-
treatment are shown in Fig. 5I and J. In untreated cells,
the majority of dihydrolipoamide dehydrogenase and MDM2
are in the cytosol (Fig. 7I). After Nutlin-3 treatment, the
majority of MDM2 is in the nucleus and the majority
of dihydrolipoamide dehydrogenase is in the cytoplasm
(Fig. 7J). Thus, the apparent increase in dihydrolipoamide
dehydrogenase/MDM2 aggregates in the nucleus is re-
lated to the elevated Nutlin-3 induction of MDM2 in the
nucleus.
In order to examine whether the nuclear pools of dihy-
drolipoamide dehydrogenase and MDM2 in the nucleus
are dynamic, we compared the effects of the nuclear export
inhibitor Leptomycin B on Nutlin-induced dihydrolipoamide
dehydrogenase-MDM2 nuclear foci using proximity ligation
assays. Compared to Nutlin-3 treatment (Fig. 8A and B) or
Leptomycin B treatment only (Fig. 8C and D), significantly
more MDM2:dihydrolipoamide dehydrogenase foci were
seen in the nucleus with combined treatment of Leptomycin
B and Nutlin-3 (Fig. 8E and F, quantified in G).
4 Discussion
MDM2 is a target for drug-discovery programmes aiming
to engage the p53 anti-tumor response. Recent clinical tri-
als evaluating an MDM2 inhibitor (RG7112; a member of
the Nutlin family) in sarcoma patients gave encouraging re-
sults with maintenance of stable disease [8]. Thus, innova-
tive approaches that convert the clinical response from sta-
ble disease to reduced tumor volume could establish a key
proof-of-concept for drugging MDM2 in human cancer. The
Nutlin class of MDM2 drugs activates p53 transcription func-
tion but these drugs do not inhibit MDM2 E3-ligase activ-
ity [16]. In fact, Nutlin has a partial agonist effect and can
stabilize prooncogenic components of the MDM2 protein–
protein interaction landscape such as Notch [18] (Fig. 1).
Our hypothesis is that the balance between the MDM2medi-
ated prooncogenic and proapoptotic pathways engaged by the
agonist function of Nutlin’s impacts on therapeutic outcome
[11]. This will likely be cell (patient/cancer genome) specific
and influenced by the cellular environment, especially as cell
density or cell number can impact on MDM2 levels [19] and
heterogeneity in p53 protein levels in cancers in vivo [29].
This cell density effect onMDM2protein levels (Fig. 1; [19])
complicates, methodologically, identifying “core” MDM2
interacting proteins. For instance, a key study has previously
highlighted the ability of MDM2 to promote p53 protein syn-
thesis [28] in addition to the classically known role of MDM2
to catalyze p53 protein degradation [4]. Importantly, this
former data suggested that confluence-dependent signaling
pathways regulate MDM2-mediated synthesis or degradation
of p53, with lower density promoting higher levels of MDM2
that changes the ratio of p53 synthesis to p53 protein degra-
dation [28]. These data suggest that other MDM2-binding
proteins could also be subjected to density effects on MDM2
signaling. As such a key study design we used was to incorpo-
rate cell density changes into the proteome screens aimed to
define the “core” MDM2 responsive proteins. A second key
study design was to focus on defining proteome changes at
a relatively early time point (4 h post-Nutlin-3 treatment) to
identify proteome changes more likely to respond to primary
impacts onMDM2 ligand binding before the growth arrest or
apoptotic machinery is activated. Lastly, we have also used a
label-free method for quantitative proteomics (SWATH) that
provided us with a deeper coverage of differential changes
in the steady-state proteome upon Nutlin-3 treatment
(Supporting Information Tables 1 and 2) than we had
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previously obtained using isobaric data-dependent labeling
methods [11].
By combining the SWATH acquired dataset at both den-
sities where MDM2 protein levels are different (Fig. 2A and
B), we can start to identify cell-density independent targets
in the MDM2 pathway analysis. The experimental approach
we used did not incorporate biological replicates at two cell
densities that would be required to produce statistically vali-
dated pathway maps. Nevertheless, the approach allowed us
to identify dihydrolipoamide dehydrogenase as an “outlier”
at the two densities whereMDM2 protein levels differ (Fig. 1)
and to subsequently validate its rearrangement with MDM2
in drug-treated cells. The mechanism whereby MDM2 pro-
tein levels and p53 pathway change as a function of cell den-
sity is only beginning to be defined. Phosphorylation of the
MDM2 pseudo-substrate motif can reduce is steady-state lev-
els and simultaneously reduce p53 protein levels [19]. The
kinase-phosphatase axis that targets this MDM2 motif as a
function of high cell density is not defined. In addition, the
reduction in p53 activity at high cell density has been linked
to change in cell–cell junctions, not stage of cell cycle [20]. The
changes in cell–cell junctions at high density whereby p53 ac-
tivity is suppressed might more accurately reflect intratumor
heterogeneity in vivo, where p53 protein levels show signifi-
cant heterogeneity [29]. It remains to be determined whether
the partial resistance of human cancers to MDM2 drugs in
clinical trials [8] is linked to density effects on MDM2 func-
tions. Dissecting this effect in vivomight be possible in future
as is has been shown that different metabolic zones with dis-
tinct proteomic signatures exist in different regions of the
tumor [40]. The application of existing protocols to process
microdissected formalin fixed clinical samples for proteomics
screens [41] might define such tumor heterogeneity to impact
on MDM2 drug biomarker discovery.
Using this strategy, we show that only two proteins can be
identified as changing greater than 2 x log2 as a function of
cell density; the mitochondrial protein dihydrolipoamide de-
hydrogenase and the nuclear protein LRWD1 (Fig. 2A and B).
These targets provide clues into two possibly dominant cel-
lular pathways that might be most affected by MDM2 drugs
independent of cell-cycle stage or cell density. In particular
the focus on the early time point of 4 h to capture primary
proteome changes under conditions in which p53:MDM2
complexes are reduced, we hoped to obtain new insight
into dominant biological processes of MDM2. LRWD1 is
reported to be a methylation-sensitive nucleosome interac-
tor that is recruited by histone methylation [31]. Although
LRWD1 is also reported to be a centrosomal protein [42],
its major effect appears to be as a replication origin recog-
nition complex-associated (ORCA/LRWD1), that binds to
methylated H3K9 targets and interacts with G9a/GLP and
Suv39H1 in a chromatin context-dependent manner [43].
It will be interesting to define the mechanism whereby
MDM2 might regulate the LRWD1/ORCA axis under nor-
mal conditions and howNutlin-3 impacts upon this biological
pathway.
Interestingly, many of the differentially expressed Nutlin-3
responsive proteins showed inverse changes at the loworhigh
densities. LRWD1 showed increases at both cell densities;
Mitochondrial acyl-coenzyme A thioesterase 9 ACOT9 was
upregulated at 40% cell density and suppressed at 80% cell
density; while RNA-binding motif protein 7 isoform RBM7
was suppressed at low 40% cell density and elevated at 80%
cell density (Fig. 2B). This apparent variation could reflect
true changes in MDM2 protein levels [19] and pathway sig-
naling as a function of cell density. For example, p53 protein
is stabilized at either density byNutlin-3 (Fig. 1), butMDM2 is
only stabilized at the lower density (as in Fig. 1). Alternatively,
it could reflect true variability on the kinetics of induction in
different cell populations of protein changes since the cells
were harvested four hours posttreatment to capture primary
responders. Most notably, dihydrolipoamide dehydrogenase
exhibited large fold changes but differential induction or sup-
pression as a function of the two cell densities.
In our current manuscript, we focused our validation on
the mitochondrial protein dihydrolipoamide dehydrogenase,
as suggestive evidence that MDM2 impacts onmitochondrial
proteome might be an early target of Nutlin-3 effects. This
was due to the prior evidence that p53 translocation into the
mitochondria is linked toNutlin-induced p53-mediated apop-
tosis [32]. We identified dihydrolipoamide dehydrogenase as
a novel MDM2-binding protein as judged by in vitro and
in vivo cobinding assays and linked this Nutlin-3 induced
change to a decrease in the integrity of the pyruvate dehy-
drogenase complex. This adds to our growing knowledge of
how Nutlin-3 effects the mitochondria. It not only causes p53
protein translocation, but directly effects a specific MDM2
protein–protein interaction with dihydrolipoamide dehydro-
genase with an early dissociation of the pyruvate dehydro-
genase holoenzyme complex (Fig. 9). Understanding further
the role of Nutlin-3 induced dihydrolipoamide dehydroge-
nase:MDM2 complexes in the nucleus (Fig. 9) might shed
new light on how dihydrolipoamide dehydrogenase might
control p53 activation in the nucleus or regulate otherMDM2
protein interactions in the nucleus, such as LRWD1.
In order to further evaluate the effects of cell density on the
mitochondrial proteome itself, we utilized a mitochondrial
affinity purification method that captures TOM22, a mito-
chondrial outer membrane receptor [44]. The reproducibility
in totalmitochondrial proteins identified using themitochon-
drial immunoprecipitation coupled to TMT is relatively high
using the two biological replicates. However, with an obvious
variability in the fold changes in the common mitochondrial
proteome (as defined by TOM22+ enriched material; Sup-
porting Information Tables 3 and 4), there were proteins
commonly altered in the two biological replicates. Proteins
that are affinity purified using this method are not only clas-
sically known mitochondrial proteins, but additional targets
such as histones (Table 1). Although this might suggest that
the affinity purification method artifactually captures free hi-
stones, there are prior reports on the effects of free histones
on mitochondrial organelle integrity [45–47].
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Figure 9. Model summarizing the effects of Nutlin-3 on dihydrolipoamide dehydrogenase and MDM2 localizations. (Left panel) In prolif-
erating cells, there are at least two pools of dihydrolipoamide dehydrogenase. One pool interacts predominantly with components of the
pyruvate dehydrogenase complex and the second pool with MDM2, predominantly in the cytosol. (Right panel) Following Nutlin-3 treat-
ment, perturbation of the mitochondrial proteome results in dissociation of the dihydrolipoamide dehydrogenase/dihydrolipoamide acetyl-
transferase, suggesting a disruption of pyruvate dehydrogenase holoenzyme complex. In addition, although minimal dihydrolipoamide
dehydrogenase is observed in the nucleus in untreated cells, the Nutlin-3-dependent import of MDM2 into the nucleus coincides with in-
creased dihydrolipoamide dehydrogenase: MDM2 complexes in the nucleus. It remains to be determined if the binding of dihydrolipoamide
dehydrogenase to MDM2 in the nucleus has a direct effect on p53 protein activation.
It is also important to point out that there is no compre-
hensive overlap in the proteome data using SWATH and
mitochondrial-TMT methods that define Nutlin-3 respon-
sive proteins. The SWATH method was applied to ask what
abundant total cellular proteins changes occur in response
to Nutlin-3. The Mitochondrial-TMT was applied to ask
what TOM22+ mitochondrial proteins change in response
to Nutlin-3. Technically, an explanation for this difference
could be due in part to the buffers used in lysis coupled to
the methods applied. For example, SWATH uses urea lysis
buffer that denatures all proteins from a cell pellet and can
thus capture the vast majority of cellular proteins whether
soluble or insoluble. By contrast, the mitochondrial isolation
uses soluble lysis buffers, which maintains native conforma-
tions, and leaves behind significant insoluble proteins in the
pellet after lysis and centrifugal clarification. Proteases can
also function under these native immunoprecipitation con-
ditions and the time required for mitochondrial enrichment
can result in loss of some mitochondrial binding proteins.
Thus, both methods can be considered complimentary ap-
proaches to ask distinct questions. Generally, the SWATH
can be applied to ask what abundant proteins changes in re-
sponse to Nutlin-3. The Mitochondrial-TMT is applied to ask
what TOM22+mitochondrial proteins change in response to
Nutlin-3. Lastly, although we can identify proteins that are up
or downregulated byNutlin-3 (or neutral) in the TOM22 affin-
ity purification, it is important to keep in mind that TOM22
is a receptor for the apoptotic protein Bax [48]. If Nutlin-3
impacts early on Bax release, then thismight alter the TOM22
receptor to impact on the drug-induced changes. Neverthe-
less, altogether, our data begin to provide protocols to define
specific mitochondrial biomarkers of MDM2 drug leads that
might be useful to design new combination drug leads or pro-
vide new biomarkers to measure effects of MDM2 targeted
drugs in vivo.
In conclusion MDM2 is an E3 ubiquitin ligase that func-
tions in proteostasis to control p53 function. MDM2 drugs
are just emerging as compelling agents to treat wt-p53 can-
cers that have the mdm2 gene amplified [8]. The current
class of drugs target the N-terminal allosteric peptide-binding
pocket in MDM2. However, these molecules do not inhibit
the MDM2 ubiquitin ligase function but they can activate or
inhibit MDM2 protein–protein interactions. In cell culture,
this can translate into data showing that Nutlin-3 can stabi-
lize p53 protein or Notch proteins [10]. The differential induc-
tion of tumor suppressor (p53) or oncogenic proteins (Notch)
might regulate the balance of cancer cell death or survival.
This “oncogenic” biomarker signature of Nutlin-3 might be
one reason why patients tumors do not regress after drug
treatment despite the biomarker p53 pathway being “acti-
vated” [8]. Thus, developing proteomic biomarker screens to
identify “dominant” MDM2 drug responsive proteins forms
an important platform for future patient stratification. In this
report, we use SWATH-MS to identify dominant Nutlin-3
responsive proteins as a concept screen that can be used
to identify possibly important MDM2 interacting proteins.
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Incorporated into the screen is the concept that the MDM2
interactome can change as a function of cell density and that
this builds-in “MDM2 heterogeneity” into the biomarker dis-
covery process. We validate one of the few commonly per-
turbed proteins, dihydrolipoamide dehydrogenase, a subunit
of the mitochondrial pyruvate dehydrogenase complex. We
also use orthogonal assays to evaluate Nutlin-3 effects on
the mitochondria including (i) mitotracker that defines mi-
tochondrial membrane potential; (ii) TMT screens of affinity
purified mitochondrial to determine key mitochondrial as-
sociated proteins that changed early after drug treatment;
and (iii) proximity ligation assays to demonstrate that di-
hydrolipoamide dehydrogenase protein–protein interactions
are rearranged in cells. Altogether, this platform provides a
roadmap that can be applied to clinical samples to begin to
stratify MDM2 drug treated patients and begin to link tumor
responses to MDM2 interacting biomarkers.
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